Medscape1d
SGLT2 Inhibitors Progressing to New Standard After TAVI
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
The American Journal of Managed Care1h
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...
Physician's Weekly4d
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Medical Dialogues3h
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
PharmExec9h
FDA Approves Novartis’ Vanrafia for Primary Immunoglobulin A Nephropathy
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
The American Journal of Managed Care1d
FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
PMLive7h
Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
MedPage Today on MSN1d
IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...
MedPage Today on MSN6d
SGLT2i Improves Outcomes After TAVI
As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...
Medscape3d
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
TCTMD4d
Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI
Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...